References
- McDermott AL, Dutt SN, Watkinson JC. The aetiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci 2001; 26: 82–92
- Cancer registry annual report. Department of Health, Executive Yuan, Republic of China, 2004.
- Suciu-Foca N, Buda J, McManus J, Thiem T, Reemtsma K. Impaired responsiveness of lymphocytes and serum-inhibitory factors in patients with cancer. Cancer Res 1973; 33: 2373–7
- Hsu MM, Lo RJ, Lynn TC, Hsieh T, Tu SM. Cellular immunity in nasopharyngeal carcinoma. I. Relationship between purified protein derivative test and leukocyte migration test. Taiwan Yi Xue Hui Za Zhi 1975; 74: 517–24
- Hallahan DE, Spriggs DR, Beckett MA, Kufe DW, Weichselbaum RR. Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci U S A 1989; 86: 10104–7
- Woloschak GE, Chang-Liu CM, Jones PS, Jones CA. Modulation of gene expression in Syrian hamster embryo cells following ionizing radiation. Cancer Res 1990; 50: 339–44
- Hsu MM, Ko JY, Chang YL. Elevated levels of soluble interleukin 2 receptor and tumor necrosis factor in nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 1991; 117: 1257–9
- Ozyar E, Yildiz F, Akyol FH, Atahan IL. Comparison of AJCC 1988 and 1997 classifications for nasopharyngeal carcinoma. American Joint Committee on Cancer. Int J Radiat Oncol Biol Phys 1999; 44: 1079–87
- Hsu MM, Wang KR, Lynn TC, Hsieh T, Huang SC, Tu SM. Immunologic reactivity in patients with nasopharyngeal carcinoma. Otolaryngol Head Neck Surg 1980; 88: 384–90
- Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 2003; 4: 565–73
- Anderson G.M, Nakada MT, DeWitte M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 2004; 4: 314–20
- Eggermont AM, ten Hagen TL. Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy. Curr Oncol Rep 2003; 5: 79–80
- Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4: 11–22
- Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 1998; 77: 2246–51
- Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D, Jr, Corey E. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 2003; 97: 1211–16
- Roitt IM, Cooke A, Male DK, Hay FC, Guarnotta G, Lydyard PM, et al. Idiotypic networks and their possible exploitation for manipulation of the immune response. Lancet 1981; 1: 1041–5
- Rivera, S, Keryer, C, Busson, P, Maingon, P. Nasopharyngeal carcinomas: from biology to clinic. Cancer Radiother 2005;9:55–68 in French.
- Zeng, L, Huang, XM, Lu, TX, Zheng, YQ, Chen, QJ, Chen, Y, , et al. Diagnosis of recurrent or residual nasopharyngeal carcinomas in the skull base area with F-18-fluoro-deoxyglucose positron emission tomography. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2006;41:517–20, in Chinese
- Witkowska AM. On the role of sIL-2R measurements in rheumatoid arthritis and cancers. Mediators Inflamm 2005; 2005: 121–30
- Lissoni P, Barni S, Rovelli F, Viviani S, Maestroni GJ, Conti A, et al. The biological significance of soluble interleukin-2 receptors in solid tumors. Eur J Cancer 1990; 26: 33–6